Inhibitors of pantothenate synthetase of Mycobacterium tuberculosis - a medicinal chemist perspective.

Autor:	Suresh A; Department of Chemistry, Birla Institute of Technology & Science-Pilani Hyderabad Campus, Medchal District Hyderabad-500078 Telangana India kvgc@hyderabad.bits-pilani.ac.in kvgcs.bits@gmail.com +91 40 66303527., Srinivasarao S; Department of Chemistry, Birla Institute of Technology & Science-Pilani Hyderabad Campus, Medchal District Hyderabad-500078 Telangana India kvgc@hyderabad.bits-pilani.ac.in kvgcs.bits@gmail.com +91 40 66303527., Khetmalis YM; Department of Chemistry, Birla Institute of Technology & Science-Pilani Hyderabad Campus, Medchal District Hyderabad-500078 Telangana India kvgc@hyderabad.bits-pilani.ac.in kvgcs.bits@gmail.com +91 40 66303527., Nizalapur S; School of Chemistry, UNSW, Australia Sydney NSW 2052 Australia., Sankaranarayanan M; Medicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science-Pilani Pilani Campus Pilani 333031 Rajasthan India., Gowri Chandra Sekhar KV; Department of Chemistry, Birla Institute of Technology & Science-Pilani Hyderabad Campus, Medchal District Hyderabad-500078 Telangana India kvgc@hyderabad.bits-pilani.ac.in kvgcs.bits@gmail.com +91 40 66303527.
Jazyk:	angličtina
Zdroj:	RSC advances [RSC Adv] 2020 Oct 07; Vol. 10 (61), pp. 37098-37115. Date of Electronic Publication: 2020 Oct 07 (Print Publication: 2020).
DOI:	10.1039/d0ra07398a
Abstrakt:	Tuberculosis (TB), one of the most prevalent infections, is on the rise today. Although there are drugs available in the market to combat this lethal disorder, there are several shortcomings with the current drug regimen, such as prolonged treatment period, drug resistance, high cost, etc. Hence, it is inevitable for the current researchers across the globe to embark on new strategies for TB drug discovery, which will yield highly active low cost drugs with a shorter treatment period. To achieve this, novel strategies need to be adopted to discover new drugs. Pantothenate Synthetase (PS) is one such striking drug target in Mycobacterium tuberculosis (MTB). It was observed that the pantothenate biosynthetic pathway is crucial for the pathogenicity of MTB. Pantothenate is absent in mammals and needs to be obtained from dietary sources. Hence, the pantothenate biosynthesis pathway is an impending target for emerging new therapeutics to treat TB. Worldwide, several approaches have been implemented by researchers in the quest for these inhibitors such as high-throughput screening, simulating the reaction intermediate pantoyl adenylate, use of vibrant combinatorial chemistry, hybridization approach, virtual screening of databases, inhibitors based on the crystal structure of MTB PS, etc. The present review recapitulates current developments in PS inhibitors, important analogues of numerous metabolic intermediates, and newly established inhibitors with innumerable chemical structures. Competing Interests: The authors declare that there is no conflict of interest. (This journal is © The Royal Society of Chemistry.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu